Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous FL vaccine
- Development stage
- Phase 3
- Lead developer
- Bayer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The autologous FL vaccine is a personalized therapeutic cancer vaccine developed for patients with follicular lymphoma (FL). It is created by isolating the unique immunoglobulin (idiotype, or Id) protein from a patient's own tumor cells. This Id protein is then conjugated to keyhole limpet hemocyanin (KLH), an immunogenic carrier protein, and administered subcutaneously along with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant. The goal of the therapy is to stimulate the patient’s immune system—specifically T cell responses—against their own lymphoma cells by targeting this unique idiotype antigen. The approach leverages each patient’s individual tumor antigens to generate a highly specific anti-tumor immune response[1]. This strategy has been studied in clinical trials for follicular lymphoma following chemotherapy-induced remission[1].
- Brand names
- BiovaxID
- Other names
- idiotype vaccineId-KLH vaccineautologous tumor-derived idiotype vaccine
02
Targets
γδ TCR (T-cell receptor)Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on Autologous FL vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous FL vaccine.